Why Is KODIAK SCIENCES INC (KOD) Stock Down Today?

KOD stock is down 4.71% at $93.82 as of the latest trade, following a sharp intraday selloff triggered by mixed developments in the eye disease drug space. The stock opened with a modest 0.5% gap up from the prior close but quickly reversed course after competitive updates from rival companies cast doubt on the market potential for Kodiak Sciences' pipeline. The session low reached $93.00, with volume so far at 0.3 million shares, nearly double the 3-month average.

What Happened

The decline began after Kodiak Sciences and 4D Molecular released clinical trial updates for their respective eye disease treatments. These developments raised concerns about the competitive landscape for wet AMD therapies, a key focus area for Kodiak. The selloff accelerated in the early morning hours as investors digested the data and adjusted their positions. The stock had previously surged more than 191.8% over the last eight sessions, rising from $33.80 to $98.63, but the recent volatility has pushed it to a fresh 52-week low on October 2. Meanwhile, UBS maintained a Buy rating on the stock earlier in the week, raising its price target to $120.

What The Data Shows

Kodiak Sciences opened at $99.00, reached a high of $99.90 at 9:20 AM ET, and then declined to a low of $93.00 at 10:00 AM ET. The stock is trading at $93.94 with 0.3 million shares exchanged so far, which is 0.2 times the 3-month average. Insiders, including Baker Bros. Advisors LP, have made three separate purchases totaling $157.0 million in the last 90 days. The stock has a beta of 2.18, indicating higher volatility than the broader market, and a market cap of $5.9 billion despite unprofitable earnings (TTM EPS -4.18).

What To Watch

Kodiak Sciences is not scheduled to report earnings in the near term. Investors should monitor the breadth of coverage and sentiment shifts as more trial data emerges in the competitive eye disease space.